• Sulfamonomethoxine Toxicity in Aquatic Organisms

  2026-08-15

  Huang and colleagues evaluated the acute and chronic toxicity of sulfamonomethoxine across algae, cladocerans, and medaka, providing a cross-trophic assessment of an aquaculture-relevant antibiotic. The study found that microalgae were more sensitive than cladocerans, emphasizing the need to include primary producers when assessing antibiotic residues in aquatic systems.

• Muscle-Derived BDNF Shapes Early NMJ Assembly

  2026-08-14

  The reference study shows that muscle-generated BDNF is not simply a diffusible trophic factor: it is trafficked to podosome-like structures, released in an activity- and calcium-dependent manner, and proteolytically processed to regulate early acetylcholine receptor clustering. By combining live-cell imaging, molecular perturbation, and skeletal muscle-specific knockout mice, the work connects local BDNF handling with the initial formation and nerve-dependent maturation of neuromuscular synapses.

• BMS 599626 Dihydrochloride in Senescence Assays

  2026-08-14

  BMS 599626 dihydrochloride is a selective EGFR and ErbB2 inhibitor that can serve as a mechanistic perturbation tool in oncology and cellular senescence assays. This guide connects receptor pharmacology with machine-learning-guided senolytic discovery while emphasizing assay interpretation, controls, and translational limitations.

• hiPSC Intestinal Organoids for Pharmacokinetic Studies

  2026-08-13

  Saito and colleagues established a direct three-dimensional culture workflow for generating expandable intestinal organoids from human induced pluripotent stem cells. The organoids could be propagated, cryopreserved, and differentiated into intestinal epithelial cells with enterocyte-associated metabolic and transporter activities, offering a more human-relevant platform for oral drug pharmacokinetic studies.

• Mavorixafor Hydrochloride: Assay Design Guide

  2026-08-13

  Explore AMD-070 hydrochloride as a CXCR4 antagonist through a practical assay-design framework that separates receptor signaling from nonspecific membrane effects. This guide connects mavorixafor biology with protoplast-based mechanistic controls, translational hematology, and carefully bounded anti-HIV research applications.

• Diclofenac in Human Intestinal Organoid Assays

  2026-08-12

  Discover how Diclofenac can connect non-selective COX inhibition with human iPSC-derived intestinal organoid models. This article focuses on exposure design, epithelial pharmacokinetics, assay interpretation, and the limitations that determine whether organoid data translate to inflammation research.

• D-N-Acetylgalactosamine: Protocol and QC Guide

  2026-08-12

  D-N-Acetylgalactosamine supports controlled studies of glycoprotein composition, brain heteropolysaccharides analysis, and glycosylation pathway workflows. It is suitable for aqueous or DMSO-based preparation, but not for ethanol-dependent protocols or long-term storage of prepared solutions.

• Human Intestinal Organoids for Pharmacokinetic Studies

  2026-08-11

  Saito and colleagues established a direct three-dimensional cluster-culture strategy for generating human iPSC-derived intestinal organoids with long-term expansion, differentiation, and cryopreservation potential. The resulting organoid-derived epithelial cells contained mature intestinal cell types and enterocytes with cytochrome P450 and transporter activities, supporting more human-relevant pharmacokinetic studies than conventional models alone.

• Epalrestat Workflow for Oxidative Stress Research

  2026-08-11

  Epalrestat connects polyol pathway inhibition with redox and mitochondrial assays, making it useful for diabetic neuropathy research and mechanistic Parkinson’s disease models. This guide translates recent KEAP1/Nrf2 findings into practical workflows, controls, and troubleshooting decisions for reproducible cell and animal studies.

• 2-Hydroxypropyl-β-cyclodextrin Protocol

  2026-08-10

  2-Hydroxypropyl-β-cyclodextrin (SKU B6413) is a cyclic oligosaccharide solubilizer for poorly water-soluble hydrophobic compounds, particularly molecules with aromatic or phenyl groups. This dossier-based guide supports formulation and biochemical solubility workflows, but does not establish compound-specific efficacy, pharmacokinetics, toxicity, or uses outside solubilization and excipient applications.

• Dacomitinib (PF-00299804) Research Workflow

  2026-08-09

  Build a rigorous Dacomitinib workflow that connects irreversible pan-HER signaling blockade with receptor phosphorylation, cell-cycle, apoptosis, and mitochondrial stress readouts. The approach is especially useful for EGFR-mutant lung cancer models, resistant HER2-amplified systems, and carefully controlled exploratory studies of ferroptosis biology.

• ECE-1c Stability, CK2, and Cisplatin Resistance

  2026-08-08

  Almarza et al. show that preventing Lys-6 ubiquitination stabilizes ECE-1c and promotes stemness, cisplatin resistance, and invasion in non-small cell lung cancer models. The findings connect CK2-dependent ECE-1c regulation with a non-canonical, endothelin-1-independent aggressive phenotype and provide a rationale for testing silmitasertib as a mechanistic CK2 probe.

• Diclofenac: COX Inhibition in Organoid Research

  2026-08-07

  Diclofenac is a non-selective COX inhibitor used to investigate prostaglandin biology, inflammation signaling, and pain signaling research. Its defined physicochemical profile can support reproducible assays, while human pluripotent stem cell-derived intestinal organoids provide a complementary platform for pharmacokinetic studies.

• Cyclophosphamide as an Alkylating Chemotherapeutic Agent: Wo

  2026-08-07

  Cyclophosphamide distinguishes itself as a DNA cross-linking cytotoxic compound and immunosuppressive agent, central to both apoptosis induction in cancer cells and bone marrow transplantation conditioning. This guide delivers actionable workflow optimizations, literature-backed protocol parameters, and troubleshooting strategies to maximize reproducibility and translational impact with APExBIO’s Cyclophosphamide.

• Topotecan as a Novel Topoisomerase I Inhibitor in Cancer Tre

  2026-08-06

  This article reviews the pharmacological innovation and clinical experience with topotecan, a water-soluble camptothecin analogue that selectively inhibits topoisomerase I, inducing apoptosis in cancer cells. The findings highlight topotecan's unique mechanism, pharmacokinetics, and evidence-based efficacy in various solid tumors, providing critical insight for optimizing chemotherapeutic regimens and advancing cancer research.

541 records 7/37 page Previous Next First page 上5页 678910 下5页 Last page